Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRITON3: Rucaparib vs Physician's Choice in mCRPC
NCT02975934Phase 3Completed
- Sponsor
- pharma&
- Start
- Jun 2017
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of rucaparib in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by pharma&. Primary endpoint: Radiographic Progression-free Survival up to 4 years. Started Jun 2017; status: completed.
02
Drugs
rucaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02975934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02975934.